As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.
25 Analysts have issued a Denali Therapeutics Inc. forecast:
25 Analysts have issued a Denali Therapeutics Inc. forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -522 -522 |
7%
7%
|
|
| EBIT (Operating Income) EBIT | -534 -534 |
8%
8%
|
|
| Net Profit | -479 -479 |
14%
14%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
| Head office | United States |
| CEO | Ryan Watts |
| Employees | 422 |
| Founded | 2013 |
| Website | www.denalitherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


